Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Embryonic stem cell-expressed Ras (ERAS) is a constitutively active GTPase belonging to the Ras family, expressed primarily in undifferentiated embryonic stem cells and specific contexts such as quiescent hepatic stellate cells and certain tumors. Unlike canonical RAS isoforms, ERAS is not detected in most adult tissues under normal conditions. Its protein activates the PI3K–AKT signaling pathway, contributing to cell survival, proliferation, and stemness features. Aberrant expression of ERAS is implicated in the development and progression of multiple cancers, including breast, gastric, pancreatic, and colorectal cancers. Its constitutive activity (insensitivity to GAP inactivation) is a distinctive property, making it a potential oncogenic driver when abnormally expressed in adult cells.
Constitutive activation of PI3K–AKT pathway; does not activate the RAF–MEK–ERK pathway but preferentially activates PI3Kα over other effectors
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Embryonic stem cell-expressed Ras (ERAS).